Page last updated: 2024-10-31

deoxyepinephrine and Autoimmune Diabetes

deoxyepinephrine has been researched along with Autoimmune Diabetes in 1 studies

Deoxyepinephrine: Sympathomimetic, vasoconstrictor agent.

Research Excerpts

ExcerptRelevanceReference
"Diabetes mellitus was assessed by investigating 8 type I diabetic patients, in good metabolic control and with congestive heart failure, who were studied after 3 weeks of placebo and ibopamine (100 mg t."9.06Ibopamine does not affect insulin resistance in patients with type I diabetes. ( Benzi, L; Cecchetti, P; Ciccarone, AM; Cicchetti, V; Di Cianni, G; Navalesi, R; Sabino, F, 1990)
"Diabetes mellitus was assessed by investigating 8 type I diabetic patients, in good metabolic control and with congestive heart failure, who were studied after 3 weeks of placebo and ibopamine (100 mg t."5.06Ibopamine does not affect insulin resistance in patients with type I diabetes. ( Benzi, L; Cecchetti, P; Ciccarone, AM; Cicchetti, V; Di Cianni, G; Navalesi, R; Sabino, F, 1990)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benzi, L1
Sabino, F1
Ciccarone, AM1
Cecchetti, P1
Di Cianni, G1
Cicchetti, V1
Navalesi, R1

Trials

1 trial available for deoxyepinephrine and Autoimmune Diabetes

ArticleYear
Ibopamine does not affect insulin resistance in patients with type I diabetes.
    Cardiology, 1990, Volume: 77 Suppl 5

    Topics: Adult; Blood Glucose; Cardiotonic Agents; Deoxyepinephrine; Diabetes Mellitus, Type 1; Female; Heart

1990